APAC Coronary Intravascular Imaging Market Industry Trends and Forecast to 2034: Segmented by (Technology, Product, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Overview
Market Dashboard
APAC · 2024–2034 · placeholder estimates
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the
full report.
Estimate 2024$216.3 MnPlaceholder estimate
Estimate 2025$236.0 Mn18.4% of the global market
Projected 2034$516.9 Mn 119%Adds $280.9 Mn over 9 forecast years
CAGR 2025–20349.1%Faster than 42% of 173 Medical Devices markets here
Key players5
APAC is 18.4% of the global market.
Among regions, the largest is North America at $630.3 Mn.
Philips Healthcare, Boston Scientific Corporation, Abbott Laboratories, Terumo Corporation, Infraredx (see all)
Formats
PDF, PPTX, XLSX
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
The APAC Coronary Intravascular Imaging Market Analysis Executive Summary
Coronary intravascular imaging uses IVUS and OCT catheters to see inside heart arteries and guide stent placement.
Key segments of the coronary Intravascular Imaging market include technology (IVUS, OCT and NIRS) and product (Catheters and Consoles).
Asia Pacific Coronary Intravascular Imaging market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.
Heart disease remains the leading cause of death worldwide. An ageing population, more minimally invasive procedures and strong clinical evidence for newer devices are driving the coronary Intravascular Imaging market.
Opportunity
Less invasive procedures, remote monitoring of implanted devices and rising access to cardiac care in emerging markets give the coronary Intravascular Imaging market room to grow.
Market Restraints
High device prices, the need for trained specialists, reimbursement pressure and product recalls hold back the coronary Intravascular Imaging market.
Competitive Landscape for Coronary Intravascular Imaging Market in APAC
The coronary Intravascular Imaging market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Healthcare Policies and Regulatory Landscape for Coronary Intravascular Imaging Market in APAC
Coronary Intravascular Imaging in APAC: rules and payment
In some of the countries we cover here, medical devices are regulated by TGA (Australia)[1], NMPA (China)[2], MDACS (Hong Kong)[3], CDSCO (India)[4], PMDA (Japan)[5], MDA (Malaysia)[6], Medsafe (WAND) (New Zealand)[7], FDA Philippines (Philippines)[8], HSA (Singapore)[9] and Thai FDA (Thailand)[10]. How care is paid for in some of these countries: Medicare and the PBS (Australia)[11], basic medical insurance (China)[12], the Hospital Authority (Hong Kong)[13], Ayushman Bharat PM-JAY (India)[14], public health insurance (Japan)[15], subsidised public care (Malaysia)[16], Pharmac (New Zealand)[17], PhilHealth (Philippines)[18], MediShield Life (Singapore)[19] and the Universal Coverage Scheme (Thailand)[20].
Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how coronary Intravascular Imaging products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in APAC.
2.2 Market Size, Growth Prospects and Key findings
3 Market Dynamics
3.1 Market Growth Drivers Analysis
3.2 Market Restraints Analysis
4 Market Segmentation
4.1 By Technology
4.2 By Product
4.3 By End User
5 By Market Share
5.1 Market Analysis, Insights and Forecast – By Revenue
6 Competitive Landscape
6.1 Major Top Market Players Products in Pipeline
6.2 R&D Initiatives
6.3 Notable recent Deals
6.3.1 Strategic Divestments
6.3.2 Mergers & Acquisitions
6.3.3 Partnerships
6.3.4 Joint Ventures
7 Key Company Profiles
7.1 Philips
7.2 Boston Scientific
7.3 Abbott Laboratories
7.4 Terumo
7.5 Infraredx
8 Healthcare Policies and Regulatory Landscape
8.1 Policy changes and Reimbursement scenario
8.2 Government Initiatives / Intervention programs
The coronary Intravascular Imaging market can be segmented based on various criteria, including technology, product and end user. Here's a breakdown of the market segmentation
Sources:PubMed (US National Library of Medicine),
ClinicalTrials.gov,
WHO Global Health Observatory.
Fetched 15 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
How big is the Coronary Intravascular Imaging market in Asia Pacific?
Placeholder estimate: about $236.0 Mn in 2025, rising to about $516.9 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Coronary Intravascular Imaging market in Asia Pacific growing?
Placeholder estimate: about 9.1% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Coronary Intravascular Imaging market report cover?
The report splits the market by technology (IVUS, OCT, NIRS), product (Catheters, Consoles) and end user (Hospitals, Ambulatory Surgical Centers, Diagnostic Centers, Home Care Settings).
Who are the key players in the Coronary Intravascular Imaging market?
Key players include Philips Healthcare, Boston Scientific Corporation, Abbott Laboratories, Terumo Corporation and Infraredx.
What is driving the Coronary Intravascular Imaging market?
Heart disease remains the leading cause of death worldwide. An ageing population, more minimally invasive procedures and strong clinical evidence for newer devices are driving the coronary Intravascular Imaging market.
How much research is published on Coronary Intravascular Imaging?
PubMed lists 232 papers on Coronary Intravascular Imaging added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.